| Market Capitalization (Millions $) |
1,880 |
| Shares
Outstanding (Millions) |
63 |
| Employees |
170 |
| Revenues (TTM) (Millions $) |
32 |
| Net Income (TTM) (Millions $) |
-170 |
| Cash Flow (TTM) (Millions $) |
-116 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Stoke Therapeutics Inc. is a biotechnology company that is focused on developing innovative therapies for patients with severe genetic diseases, particularly diseases caused by haploinsufficiency. Haploinsufficiency is a genetic condition where a person has only one functioning copy of a gene instead of the normal two, leading to a reduced expression of the gene and potentially causing disease.
Stoke Therapeutics is leveraging its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform to address this issue. The TANGO platform utilizes antisense oligonucleotides to enhance the expression of the non-mutated copy of the gene, increasing the production of the specific protein and potentially treating the underlying disease.
The company aims to develop therapies for a range of genetic disorders, including genetic epilepsies, neurodevelopmental disorders, and other diseases that are not adequately addressed by current treatment options. Stoke Therapeutics is conducting clinical trials and partnering with academic institutions and industry collaborators to accelerate the development and commercialization of its therapies.
Overall, Stoke Therapeutics is at the forefront of developing innovative treatments for severe genetic diseases, using its TANGO platform to enhance gene expression and offer potential therapeutic options for patients in need.
Company Address: 45 Wiggins Ave Bedford 1730 MA
Company Phone Number: 430-8200 Stock Exchange / Ticker: NASDAQ STOK
|
12.24% 
64.75 %